Y
Ying Zhang
Researcher at Harvard University
Publications - 13
Citations - 1907
Ying Zhang is an academic researcher from Harvard University. The author has contributed to research in topics: Cytotoxic T cell & T cell. The author has an hindex of 7, co-authored 11 publications receiving 778 citations. Previous affiliations of Ying Zhang include Boston Children's Hospital & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Gasdermin E suppresses tumour growth by activating anti-tumour immunity.
Zhibin Zhang,Zhibin Zhang,Ying Zhang,Ying Zhang,Shiyu Xia,Shiyu Xia,Qing Kong,Shunying Li,Xing Liu,Xing Liu,Xing Liu,Caroline Junqueira,Caroline Junqueira,Caroline Junqueira,Karla F. Meza-Sosa,Karla F. Meza-Sosa,Karla F. Meza-Sosa,Temy Mo Yin Mok,Temy Mo Yin Mok,Temy Mo Yin Mok,James Ansara,James Ansara,Satyaki Sengupta,Yandan Yao,Hao Wu,Hao Wu,Judy Lieberman,Judy Lieberman +27 more
TL;DR: The gasdermin E protein is shown to act as a tumour suppressor: it is cleaved by caspase 3 and granzyme B and leads to pyroptosis of cancer cells, provoking an immune response to the tumour.
Journal ArticleDOI
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Jun Jacob Hu,Jun Jacob Hu,Xing Liu,Xing Liu,Xing Liu,Shiyu Xia,Shiyu Xia,Zhibin Zhang,Zhibin Zhang,Ying Zhang,Ying Zhang,Jiangning Zhao,Jiangning Zhao,Jiangning Zhao,Jianbin Ruan,Jianbin Ruan,Jianbin Ruan,Xuemei Luo,Xiwen Lou,Yang Bai,Junhong Wang,L. Robert Hollingsworth,L. Robert Hollingsworth,Venkat Giri Magupalli,Venkat Giri Magupalli,Li Zhao,Li Zhao,Hongbo R. Luo,Hongbo R. Luo,Justin Kim,Judy Lieberman,Judy Lieberman,Hao Wu,Hao Wu +33 more
TL;DR: Disulfiram, an FDA-approved drug for treating alcoholism, is identified as an inhibitor of pore formation by GSDMD but not other members of the GSDM family, providing new therapeutic indications for repurposing this safe drug to counteract inflammation.
Journal ArticleDOI
Enhancing CD8 + T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.
Ying Zhang,Ying Zhang,Raj K. Kurupati,Ling Liu,Xiangyang Zhou,Gao Zhang,Abeer Hudaihed,Flavia Filisio,Wynetta Giles-Davis,Xiaowei Xu,Giorgos C. Karakousis,Lynn M. Schuchter,Wei Xu,Ravi K. Amaravadi,Min Xiao,Norah Sadek,Clemens Krepler,Meenhard Herlyn,Gordon J. Freeman,Joshua D. Rabinowitz,Hildegund C.J. Ertl +20 more
TL;DR: Using mouse melanoma models, it is reported that CD8+ TILs enhance peroxisome proliferator-activated receptor (PPAR)-α signaling and catabolism of fatty acids (FAs) when simultaneously subjected to hypoglycemia and hypoxia.
Journal ArticleDOI
Identifying the pathways required for coping behaviours associated with sustained pain.
Tianwen Huang,Shing-Hong Lin,Nathalie M. Malewicz,Yan Zhang,Yan Zhang,Yan Zhang,Ying Zhang,Ying Zhang,Martyn Goulding,Robert H. LaMotte,Qiufu Ma +10 more
TL;DR: In mice, the ablation of spinal neurons that co-express TAC1 and LBX1 leads to the loss of coping responses to sustained pain without affecting reflexive defensive reactions to external threats, and challenges the validity of using Reflexive defensive responses to measure sustained pain.
Journal ArticleDOI
Starved and Asphyxiated: How Can CD8+ T Cells within a Tumor Microenvironment Prevent Tumor Progression
Ying Zhang,Hildegund C.J. Ertl +1 more
TL;DR: It is proposed that manipulating the metabolism of TILs to more efficiently utilize nutrients, especially during intermittent periods of hypoxia could maximize their performance, prolong their survival and improve the efficacy of active cancer immunotherapy.